Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

被引：8

作者：

Shalabi, Haneen ^{[1
]}

Yates, Bonnie ^{[1
]}

Shahani, Shilpa ^{[1
]}

Qin, Haiying ^{[1
]}

HIghfill, Steven L. ^{[1
]}

Panch, Sandhya ^{[1
]}

Tran, Minh ^{[1
]}

Stroncek, David ^{[1
]}

Hoffman, Leah ^{[1
]}

Little, Lauren ^{[1
]}

Graap, Katherine ^{[1
]}

Stetler-Stevenson, Maryalice ^{[1
]}

Yuan, Constance ^{[1
]}

Wang, Hao-Wei ^{[1
]}

Fry, Terry J. ^{[2
,3
]}

Shah, Nirali N. ^{[1
]}

机构：

[1] NIH, Bldg 10, Bethesda, MD 20892 USA

[2] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[3] Ctr Canc & Blood Disorders, Aurora, CO USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-CT051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT051

引用

页数：4

共 50 条

[1] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li, Wenjie
Ding, Lixia
Shi, Wenhua
Wan, Xinyu
Yang, Xiaomin
Yang, Jing
Wang, Tianyi
Song, Lili
Wang, Xiang
Ma, Yani
Luo, Chengjuan
Tang, Jingyan
Gu, Longjun
Chen, Jing
Lu, Jun
Tang, Yanjing
Li, Benshang
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[2] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Wenjie Li
Lixia Ding
Wenhua Shi
Xinyu Wan
Xiaomin Yang
Jing Yang
Tianyi Wang
Lili Song
Xiang Wang
Yani Ma
Chengjuan Luo
Jingyan Tang
Longjun Gu
Jing Chen
Jun Lu
Yanjing Tang
Benshang Li
Journal of Translational Medicine, 21
[3] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
Yang, Tingting
Dong, Yetian
Zhang, Mingming
Feng, Jingjing
Fu, Shan
Xiao, Pingnan
Hong, Ruimin
Xu, Huijun
Cui, Jiazhen
Huang, Simao
Wei, Guoqing
Chang, Alex H.
Huang, He
Hu, Yongxian
BLOOD, 2024, 144 : 2819 - 2819
[4] Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Maude, Shannon L.
Barrett, David M.
Ambrose, David E.
Rheingold, Susan R.
Aplenc, Richard
Teachey, David T.
Callahan, Colleen
Barker, Christine S.
Mudambi, Maya
Shaw, Pamela A.
Brogdon, Jennifer
Young, Regina M.
Scholler, John
Loew, Andreas
Marcucci, Katherine T.
Finklestein, Jeffrey
Kulikovskaya, Irina
Nazimuddin, Farzana
Zheng, Zhaohui
Levine, Bruce L.
Porter, David L.
Lacey, Simon F.
Melenhorst, Jan J.
June, Carl H.
Grupp, Stephan A.
BLOOD, 2015, 126 (23)
[5] DUAL CD19/CD22 CAR T CELLS SHOW FEASIBILITY IN PEDIATRIC/YOUNG ADULT B-ALL
不详
CANCER DISCOVERY, 2021, 11 (12) : 2958 - 2958
[6] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang, Lefu
Li, Jingjing
Yang, Junfang
Zhang, Xian
Zhang, Min
He, Jiujiang
Zhang, Gailing
Li, Wenqian
Wang, Hui
Li, Jianqiang
Lu, Peihua
CELLS, 2022, 11 (24)
[7] Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/Refractory ALL Patients
Tang, Xiaowen
Kang, Liqing
Qi, Wei
Cui, Wei
Dai, Haiping
Li, Zheng
Yin, Jia
Qu, Changju
Xu, Ting
Zhu, Xiaming
Yu, Lei
Wu, Depei
BLOOD, 2019, 134
[8] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
Tu, Sanfang
Zhou, Lijuan
Huang, Rui
Zhou, Xuan
Yang, Jilong
Li, Meifang
Jin, Bo
Wang, Langqi
Zhuo, Yaqi
Chen, Huifang
Chang, Lung-Ji
Li, Yuhua
BLOOD, 2023, 142
[9] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
Maus, Marcela V.
LANCET, 2021, 398 (10299): : 466 - 467
[10] CD19/CD22 Dual-Targeted CAR-TTherapy Active in Relapsed/Refractory DLBCL
不详
ONCOLOGIST, 2020, 25 : S12 - S13

← 1 2 3 4 5 →